Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16742092 | 0.97 | CALM1 (0.45) | CALM1TSHRALDH1A1LOXL2IDO1 | |
| SCHEMBL17398903 | 0.94 | CALM1 (0.43) | CALM1TSHRALDH1A1LOXL2IDO1 | |
| Potassium Ion SCHEMBL19260323 | 0.76 | IDO1 (0.46) | LOXL2IDO1TRPA1MAOBTAAR1 | |
| Potassium Ion SCHEMBL14332510 | 0.74 | ALDH1A1 (0.46) | TSHRALDH1A1LOXL2IDO1TRPA1 | |
| SCHEMBL308277 | 0.73 | CALM1 (0.50) | CALM1TSHRALDH1A1LOXL2IDO1 | |
| SCHEMBL19260349 | 0.72 | IDO1 (0.48) | LOXL2IDO1TRPA1MAOBTAAR1 | |
| SCHEMBL8754878 | 0.71 | CALM1 (0.47) | CALM1TSHRALDH1A1LOXL2IDO1 | |
| Diphenylmethane SCHEMBL18550456 | 0.71 | CALM1 (0.75) | CALM1TSHRALDH1A1LOXL2IDO1 | |
| SCHEMBL19260366 | 0.70 | TAAR1 (0.52) | ALDH1A1IDO1MAOBSMN1; SMN2TAAR1 | |
| SCHEMBL19260397 | 0.70 | IDO1 (0.46) | ALDH1A1IDO1MAOBCYP2A6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12595230-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2026-04-07 | — | — | US | disclosed |
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3544726-B1 | PHOTOCHEMISTRY DEVICE | HEPATOCHEM INC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4688772-A1 | BIARYL DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2026-01-15 | — | — | US | disclosed |
| WO-2025264954-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250367649-A1 | PHOTOCATALYSTS, PREPARATION AND USE THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) | 2025-12-04 | — | — | US | disclosed |
| EP-2114898-A2 | NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS | Amgen Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-1899322-B1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009076602-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | WYETH (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009073669-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20090088429-A1 | Isoquinoline Derivatives | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008103277-A2 | NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS | AMGEN INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| EP-1899322-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007000240-A1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | POLB, POLA1, POLN | CALM1 2959/4885TSHR 1503/4885ALDH1A1 824/4885 |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | S1PR1, S1PR2, S1PR4 | CALM1 1482/4885TSHR 1154/4885ALDH1A1 708/4885 |
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | HGF, HGFAC, MET | CALM1 4037/4885TSHR 3180/4885ALDH1A1 293/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CALM1 1559/4885TSHR 3558/4885ALDH1A1 4701/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CALM1 1451/4885TSHR 3460/4885ALDH1A1 4718/4885 |
| US-20250367649-A1 | PHOTOCATALYSTS, PREPARATION AND USE THEREOF | PPOX, AOX1, CYP3A7 | CALM1 4598/4885TSHR 4214/4885ALDH1A1 199/4885 |
| US-12595230-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | FSHR, CYP19A1, GPER1 | CALM1 2504/4885TSHR 53/4885ALDH1A1 936/4885 |
| US-20090088429-A1 | Isoquinoline Derivatives | MYLK2, MYLK, RHOT2 | CALM1 425/4885TSHR 4527/4885ALDH1A1 2871/4885 |
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | NTPCR, NT5C2, NT5E | CALM1 3511/4885TSHR 314/4885ALDH1A1 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.